These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22844354)

  • 1. Advantages of the quenching probe method over other PCR-based methods for detection of the JAK2 V617F mutation.
    Ono A; Okuhashi Y; Takahashi Y; Itoh M; Nara N; Tohda S
    Oncol Lett; 2012 Aug; 4(2):205-208. PubMed ID: 22844354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of different methodologies to detect the
    Didone A; Nardinelli L; Marchiani M; Ruiz ARL; de Lima Costa AL; Lima IS; Santos NM; Sanabani SS; Bendit I
    Pract Lab Med; 2016 Apr; 4():30-37. PubMed ID: 28856190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validating the Sensitivity of High-Resolution Melting Analysis for JAK2 V617F Mutation in the Clinical Setting.
    Lin CY; Ho CM; Tamamyan G; Yang SF; Peng CT; Chang JG
    J Clin Lab Anal; 2016 Nov; 30(6):838-844. PubMed ID: 27169616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of the JAK2 mutation in myeloproliferative neoplasms by asymmetric PCR with unlabeled probe and high-resolution melt analysis.
    Cao HC; Lin J; Qian J; Yao DM; Li Y; Yang J; Chen Q; Chai HY; Xiao GF
    J Clin Lab Anal; 2011; 25(4):300-4. PubMed ID: 21786333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of the MYD88 mutation by the combination of the allele-specific PCR and quenching probe methods.
    Nogami S; Kawaguchi-Ihara N; Shiratori E; Ohtaka M; Itoh M; Tohda S
    Int J Lab Hematol; 2017 Apr; 39(2):163-168. PubMed ID: 28042684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
    Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
    J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera.
    Wu Z; Yuan H; Zhang X; Liu W; Xu J; Zhang W; Guan M
    PLoS One; 2011; 6(10):e26534. PubMed ID: 22028900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR.
    Kinz E; Leiherer A; Lang AH; Drexel H; Muendlein A
    Int J Lab Hematol; 2015 Apr; 37(2):217-24. PubMed ID: 24963593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.
    Waterhouse M; Follo M; Pfeifer D; von Bubnoff N; Duyster J; Bertz H; Finke J
    Ann Hematol; 2016 Apr; 95(5):739-44. PubMed ID: 26931113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases.
    Rapado I; Albizua E; Ayala R; Hernández JA; Garcia-Alonso L; Grande S; Gallardo M; Gilsanz F; Martinez-Lopez J
    Ann Hematol; 2008 Sep; 87(9):741-9. PubMed ID: 18575865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a high resolution melting analysis assay for rapid identification of JAK2 V617F missense mutation and its validation.
    Moradabadi A; Farsinejad A; Khansarinejad B; Fatemi A
    Exp Hematol Oncol; 2019; 8():10. PubMed ID: 31165012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
    Lee E; Lee KJ; Park H; Chung JY; Lee MN; Chang MH; Yoo J; Lee H; Kong SY; Eom HS
    Ann Lab Med; 2018 Mar; 38(2):147-154. PubMed ID: 29214759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the reannealing- instead of melting-curve in the detection of JAK2 V617F mutation by HRM method.
    Moradabadi A; Fatemi A; Noroozi-Aghideh A
    J Blood Med; 2019; 10():235-241. PubMed ID: 31413649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superiority of Droplet Digital PCR Over Real-Time Quantitative PCR for
    La Rocca F; Grieco V; Ruggieri V; Zifarone E; Villani O; Zoppoli P; Russi S; Laurino S; Falco G; Calice G; Marinaccio A; Natalicchio MI; Albano F; Musto P
    Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32150880
    [No Abstract]   [Full Text] [Related]  

  • 16. [Usefulness of real-time semi-quantitative PCR, JAK2 MutaScreen kit for JAK2 V617F screening].
    Chae H; Lee JH; Lim J; Jung SW; Kim M; Kim Y; Han K; Cho BS; Cho SG; Lee JW; Min WS
    Korean J Lab Med; 2009 Jun; 29(3):243-8. PubMed ID: 19571623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection.
    Zapparoli GV; Jorissen RN; Hewitt CA; McBean M; Westerman DA; Dobrovic A
    BMC Cancer; 2013 Apr; 13():206. PubMed ID: 23617802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients.
    Macedo LC; Santos BC; Pagliarini-e-Silva S; Pagnano KB; Rodrigues C; Quintero FC; Ferreira ME; Baraldi EC; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
    Int J Lab Hematol; 2015 Oct; 37(5):654-60. PubMed ID: 25959311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
    Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
    Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
    Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
    Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.